Are you over 18 and want to see adult content?
More Annotations
![A complete backup of https://balkanje.com/turske-serije/ljubav-vjera-nada/](https://www.archivebay.com/archive6/images/e578f56b-774d-4f23-9210-82e4a869cb91.png)
A complete backup of https://balkanje.com/turske-serije/ljubav-vjera-nada/
Are you over 18 and want to see adult content?
![A complete backup of https://balkanje.com/turske-serije/adanali-2008/](https://www.archivebay.com/archive6/images/10a1c3ac-7b26-4691-a7ed-1c905eddf73e.png)
A complete backup of https://balkanje.com/turske-serije/adanali-2008/
Are you over 18 and want to see adult content?
![A complete backup of https://balkanje.com/latino-serije/ljubavnici-2005/](https://www.archivebay.com/archive6/images/3490a6a7-3c3c-413e-bc7e-64f3223af74c.png)
A complete backup of https://balkanje.com/latino-serije/ljubavnici-2005/
Are you over 18 and want to see adult content?
![A complete backup of https://balkanje.com/latino-serije/control-z-2020/](https://www.archivebay.com/archive6/images/19cbb73a-8eb0-4a40-ade4-4bd04ea5423a.png)
A complete backup of https://balkanje.com/latino-serije/control-z-2020/
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of thefacialroom.com.au](https://www.archivebay.com/archive2/96436264-34cb-4e48-8f88-fc97acc5b8c8.png)
A complete backup of thefacialroom.com.au
Are you over 18 and want to see adult content?
![A complete backup of diacheirosrestaurant.gr](https://www.archivebay.com/archive2/34d52768-a374-4049-96ae-becd83f6dc8b.png)
A complete backup of diacheirosrestaurant.gr
Are you over 18 and want to see adult content?
![A complete backup of opcionempleo.com.do](https://www.archivebay.com/archive2/655c11a7-f7b1-40a2-af67-b52a5f60d6c7.png)
A complete backup of opcionempleo.com.do
Are you over 18 and want to see adult content?
![A complete backup of arielmotor.co.uk](https://www.archivebay.com/archive2/911aaeb2-5f12-44c6-a943-b36f036c8fc0.png)
A complete backup of arielmotor.co.uk
Are you over 18 and want to see adult content?
![A complete backup of lucerotabs.blogspot.com](https://www.archivebay.com/archive2/ac060888-6753-4763-945c-fe8fa9668964.png)
A complete backup of lucerotabs.blogspot.com
Are you over 18 and want to see adult content?
Text
guided
CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
EXPLORING THE CONNECTION BETWEEN GUT HEALTH AND HAIR The Gut/Hair Connection. Evolving indicators suggest a connection between gut health and hair growth that remains to be proven. For example, when two refractory alopecia universalis patients underwent fecal-matter transplant (FMT) for recurrent Clostridium difficile infection (CDI), they experienced subsequent hair regrowth.This suggests gut flora composition may be associated with immune OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFUL Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
EXPLORING THE CONNECTION BETWEEN GUT HEALTH AND HAIR The Gut/Hair Connection. Evolving indicators suggest a connection between gut health and hair growth that remains to be proven. For example, when two refractory alopecia universalis patients underwent fecal-matter transplant (FMT) for recurrent Clostridium difficile infection (CDI), they experienced subsequent hair regrowth.This suggests gut flora composition may be associated with immune OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFUL Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and PRACTICAL DERMATOLOGY Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. TOPICAL STEROID WITHDRAWAL IN ATOPIC DERMATITIS Management of Atopic Dermatitis. AD, a highly prevalent and complex, chronic inflammatory skin condition, is thought to be due to immune dysregulation, skin barrier dysfunction, and dysbiosis. 8 Interestingly, the increasing understanding of psoriasis as a systemic disease has shed light on the management of AD. Psoriasis has been the model for targeted inflammatory disease FDA APPROVES EXPANDED USE OF THE RECELL SYSTEM FOR The U.S. Food and Drug Administration (FDA) approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. MERZ AESTHETICS LAUNCHES NEW ONLINE AESTHETICS EDUCATION June 9, 2021 Merz Aesthetics Launches New Online Aesthetics Education Platform Established by Merz Aesthetics Global Medical Affairs, the Medical Forum provides on-demand content focused on medical aesthetics innovations and research to create more accessible scientificexchange.
ACKNOWLEDGEMENT: THE FREQUENTLY FORGOTTEN CUSTOMER SERVICE The first is caring about your customer, which will guide you to make better decisions. The second is communicating well, which can change the outcome of a conversation. For better communication, follow the acronym LAER: Listen, Acknowledge, Explore, and Respond. This article will focus on acknowledge, as it tends to be the most frequently EULAR: DAY SHOWN BENEFIT OF TREMFYA IN PSA AFTER ANTI-TNF New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Tremfya is a selective IL-23 inhibitor from Janssen Pharmaceutical Companies of Johnson & Johnson.. In the COSMOS Phase 3b study, significantly higher proportions of patients treated CELLFX FROM PULSE BIOSCIENCES CLEARED IN CANADA The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. SCIENTIFICALLY SPEAKING: NEW DIRECTIONS IN ACNE MANAGEMENT From the optimal, safe use of isotretinoin to the proper role for systemic antibiotics and beyond, there are multiple areas of systemic acne care that deserve attention. In the second of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, NURX ADDS ROSACEA CARE TO LIST OF SERVICES Nurx, now includes rosacea treatment in its at-home dermatology services. The service consists of a consultation with a Nurx medical provider, a personalized treatment plan for rosacea, home delivery of medication, and ongoing care. THE ROLE OF ORAL CONTRACEPTIVE PILLS IN THE ACNE TREATMENT O ral contraceptive pills (OCP s) can be an effective treatment option for women with acne, but understanding the risks and identifying the ideal candidates for therapy is essential.Ahead, experts discuss when OCPs are the right choice, which patients are ideal candidates, barriers to treatment, and the importance of patient education andscreening.
PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
NATROBA NOW APPROVED FOR SCABIES IN ADULTS AND CHILDREN AS Natroba™ (spinosad) Topical Suspension, 0.9% is now approved as a topical treatment for scabies infestations in adult and pediatric patients four years of age and older. ParaPRO received approval of a supplemental New Drug Application (sNDA) for Natroba™, which has been approved for the topical treatment of head lice infestations since 2011. It is currently the most frequently prescribed TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
NATROBA NOW APPROVED FOR SCABIES IN ADULTS AND CHILDREN AS Natroba™ (spinosad) Topical Suspension, 0.9% is now approved as a topical treatment for scabies infestations in adult and pediatric patients four years of age and older. ParaPRO received approval of a supplemental New Drug Application (sNDA) for Natroba™, which has been approved for the topical treatment of head lice infestations since 2011. It is currently the most frequently prescribed TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and MERZ AESTHETICS LAUNCHES NEW ONLINE AESTHETICS EDUCATION June 9, 2021 Merz Aesthetics Launches New Online Aesthetics Education Platform Established by Merz Aesthetics Global Medical Affairs, the Medical Forum provides on-demand content focused on medical aesthetics innovations and research to create more accessible scientificexchange.
VITILIGO: ORAL AND TOPICAL JAKS SHOW PROMISE The JAK 1/3 inhibitor tofacitinib (Xeljanz, Pfizer) was FDA approved in 2012 for the treatment of moderate to severe rheumatoid arthritis and then later also approved for psoriatic arthritis. Oral and topical formulations have demonstrated safety and efficacy for the treatment of plaque psoriasis and oral tofacitinib for treating alopecia. SKINSAFE, CVS NAME TOP 25 2021 SUNSCREEN AWARD WINNERS FOR June 7, 2021 SkinSAFE, CVS Name Top 25 2021 Sunscreen Award Winners for Sensitive Skin Developed in collaboration with Mayo Clinic, SkinSAFE helps people with sensitive skin find products that meet their sensitive skin needs, and to avoid products that may contain potential irritants. FDA APPROVES EXPANDED USE OF THE RECELL SYSTEM FOR The U.S. Food and Drug Administration (FDA) approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. EULAR: DAY SHOWN BENEFIT OF TREMFYA IN PSA AFTER ANTI-TNF New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Tremfya is a selective IL-23 inhibitor from Janssen Pharmaceutical Companies of Johnson & Johnson.. In the COSMOS Phase 3b study, significantly higher proportions of patients treated CELLFX FROM PULSE BIOSCIENCES CLEARED IN CANADA The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFUL Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. FDA GRANTS BREAKTHROUGH DEVICE STATUS TO ALPHA DART FOR June 8, 2021 FDA Grants Breakthrough Device Status to Alpha DaRT for SCC The FDA granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma of the skin and oral cavity without curative standard ofcare.
SCIENTIFICALLY SPEAKING: NEW DIRECTIONS IN ACNE MANAGEMENT From the optimal, safe use of isotretinoin to the proper role for systemic antibiotics and beyond, there are multiple areas of systemic acne care that deserve attention. In the second of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, ALLERGAN AESTHETICS, BOTOX COSMETIC UNVEIL ‘SEE YOURSELF Allergan Aesthetics is launching 'See Yourself', a new campaign featuring documentary-style shorts that tell the stories of real BotoxCosmetic patients.
PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
NATROBA NOW APPROVED FOR SCABIES IN ADULTS AND CHILDREN AS Natroba™ (spinosad) Topical Suspension, 0.9% is now approved as a topical treatment for scabies infestations in adult and pediatric patients four years of age and older. ParaPRO received approval of a supplemental New Drug Application (sNDA) for Natroba™, which has been approved for the topical treatment of head lice infestations since 2011. It is currently the most frequently prescribed TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
NATROBA NOW APPROVED FOR SCABIES IN ADULTS AND CHILDREN AS Natroba™ (spinosad) Topical Suspension, 0.9% is now approved as a topical treatment for scabies infestations in adult and pediatric patients four years of age and older. ParaPRO received approval of a supplemental New Drug Application (sNDA) for Natroba™, which has been approved for the topical treatment of head lice infestations since 2011. It is currently the most frequently prescribed TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and MERZ AESTHETICS LAUNCHES NEW ONLINE AESTHETICS EDUCATION June 9, 2021 Merz Aesthetics Launches New Online Aesthetics Education Platform Established by Merz Aesthetics Global Medical Affairs, the Medical Forum provides on-demand content focused on medical aesthetics innovations and research to create more accessible scientificexchange.
VITILIGO: ORAL AND TOPICAL JAKS SHOW PROMISE The JAK 1/3 inhibitor tofacitinib (Xeljanz, Pfizer) was FDA approved in 2012 for the treatment of moderate to severe rheumatoid arthritis and then later also approved for psoriatic arthritis. Oral and topical formulations have demonstrated safety and efficacy for the treatment of plaque psoriasis and oral tofacitinib for treating alopecia. SKINSAFE, CVS NAME TOP 25 2021 SUNSCREEN AWARD WINNERS FOR June 7, 2021 SkinSAFE, CVS Name Top 25 2021 Sunscreen Award Winners for Sensitive Skin Developed in collaboration with Mayo Clinic, SkinSAFE helps people with sensitive skin find products that meet their sensitive skin needs, and to avoid products that may contain potential irritants. FDA APPROVES EXPANDED USE OF THE RECELL SYSTEM FOR The U.S. Food and Drug Administration (FDA) approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. EULAR: DAY SHOWN BENEFIT OF TREMFYA IN PSA AFTER ANTI-TNF New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Tremfya is a selective IL-23 inhibitor from Janssen Pharmaceutical Companies of Johnson & Johnson.. In the COSMOS Phase 3b study, significantly higher proportions of patients treated CELLFX FROM PULSE BIOSCIENCES CLEARED IN CANADA The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFUL Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. FDA GRANTS BREAKTHROUGH DEVICE STATUS TO ALPHA DART FOR June 8, 2021 FDA Grants Breakthrough Device Status to Alpha DaRT for SCC The FDA granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma of the skin and oral cavity without curative standard ofcare.
SCIENTIFICALLY SPEAKING: NEW DIRECTIONS IN ACNE MANAGEMENT From the optimal, safe use of isotretinoin to the proper role for systemic antibiotics and beyond, there are multiple areas of systemic acne care that deserve attention. In the second of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, ALLERGAN AESTHETICS, BOTOX COSMETIC UNVEIL ‘SEE YOURSELF Allergan Aesthetics is launching 'See Yourself', a new campaign featuring documentary-style shorts that tell the stories of real BotoxCosmetic patients.
PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
INVESTMENTS 101: CALCULATING CAPITAL EQUIPMENT PURCHASE While every physician and practice is different, Dr. Kaminer emphasizes a general rule of thumb regarding capital equipment purchases that may aid in early decision-making: “Aim to have the cost of a procedure (consumables plus device carrying costs) be lessthan 25 percent of
TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and TNF INHIBITORS AND THE RISK OF MELANOMA ONCOLOGY ATC AuGusT 2013 PRACTICAL DERMATOLOGY 47 Other studies have reached similar conclusions.7,8 However, the incidence of non-melanoma skin cancer has been PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
INVESTMENTS 101: CALCULATING CAPITAL EQUIPMENT PURCHASE While every physician and practice is different, Dr. Kaminer emphasizes a general rule of thumb regarding capital equipment purchases that may aid in early decision-making: “Aim to have the cost of a procedure (consumables plus device carrying costs) be lessthan 25 percent of
TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and TNF INHIBITORS AND THE RISK OF MELANOMA ONCOLOGY ATC AuGusT 2013 PRACTICAL DERMATOLOGY 47 Other studies have reached similar conclusions.7,8 However, the incidence of non-melanoma skin cancer has beenRECENT DEVELOPMENTS
Survey: Telederm Appointments Suitable Alternatives to Office Visits. The majority of dermatology patients find telehealth appointments to be a suitable alternative to in-person office visits, according to a survey in the Journal of Drugs in Dermatology. “Teledermatology boasts a number of benefits, including increased access to care, cost savings for patients, convenience, and, with the TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided at
ALLERGAN AESTHETICS, BOTOX COSMETIC UNVEIL ‘SEE YOURSELF Allergan Aesthetics is launching 'See Yourself', a new campaign featuring documentary-style shorts that tell the stories of real BotoxCosmetic patients.
NEW RESEARCH SHOWS HOW IMMUNE CELLS ORGANIZE THEMSELVES IN New research reveals how the skin’s immune cells organize themselves to ward off would-be intruders. Skin’s immune cells have a history of being misunderstood. SKINSAFE, CVS NAME TOP 25 2021 SUNSCREEN AWARD WINNERS FOR June 7, 2021 SkinSAFE, CVS Name Top 25 2021 Sunscreen Award Winners for Sensitive Skin Developed in collaboration with Mayo Clinic, SkinSAFE helps people with sensitive skin find products that meet their sensitive skin needs, and to avoid products that may contain potential irritants. EXPLORING THE CONNECTION BETWEEN GUT HEALTH AND HAIR The Gut/Hair Connection. Evolving indicators suggest a connection between gut health and hair growth that remains to be proven. For example, when two refractory alopecia universalis patients underwent fecal-matter transplant (FMT) for recurrent Clostridium difficile infection (CDI), they experienced subsequent hair regrowth.This suggests gut flora composition may be associated with immune FDA GRANTS BREAKTHROUGH DEVICE STATUS TO ALPHA DART FOR June 8, 2021 FDA Grants Breakthrough Device Status to Alpha DaRT for SCC The FDA granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma of the skin and oral cavity without curative standard ofcare.
CUTANEOUS SUPERFICIAL LEIOMYOSARCOMA: A TREATMENT Superficial leiomyosarcoma (SLMS) is a rare sarcoma, which is further classified as either cutaneous or subcutaneous based on dermal location and site of origin. Cutaneous SLMS have excellent outcome with rare recurrence, whereas subcutaneous SLMS have high recurrence and metastatic rates. Wide excision with 2-5cm margins hashistorically been
DERMAVANT SUBMITS NDA FOR TAPINAROF FOR PSO Dermavant Sciences has submitted a New Drug Application (NDA) to the FDA for tapinarof for the treatment of mild, moderate, and severeplaque psoriasi
PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
INVESTMENTS 101: CALCULATING CAPITAL EQUIPMENT PURCHASE While every physician and practice is different, Dr. Kaminer emphasizes a general rule of thumb regarding capital equipment purchases that may aid in early decision-making: “Aim to have the cost of a procedure (consumables plus device carrying costs) be lessthan 25 percent of
TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and TNF INHIBITORS AND THE RISK OF MELANOMA ONCOLOGY ATC AuGusT 2013 PRACTICAL DERMATOLOGY 47 Other studies have reached similar conclusions.7,8 However, the incidence of non-melanoma skin cancer has been PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
INVESTMENTS 101: CALCULATING CAPITAL EQUIPMENT PURCHASE While every physician and practice is different, Dr. Kaminer emphasizes a general rule of thumb regarding capital equipment purchases that may aid in early decision-making: “Aim to have the cost of a procedure (consumables plus device carrying costs) be lessthan 25 percent of
TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and TNF INHIBITORS AND THE RISK OF MELANOMA ONCOLOGY ATC AuGusT 2013 PRACTICAL DERMATOLOGY 47 Other studies have reached similar conclusions.7,8 However, the incidence of non-melanoma skin cancer has beenRECENT DEVELOPMENTS
Survey: Telederm Appointments Suitable Alternatives to Office Visits. The majority of dermatology patients find telehealth appointments to be a suitable alternative to in-person office visits, according to a survey in the Journal of Drugs in Dermatology. “Teledermatology boasts a number of benefits, including increased access to care, cost savings for patients, convenience, and, with the TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided at
ALLERGAN AESTHETICS, BOTOX COSMETIC UNVEIL ‘SEE YOURSELF Allergan Aesthetics is launching 'See Yourself', a new campaign featuring documentary-style shorts that tell the stories of real BotoxCosmetic patients.
NEW RESEARCH SHOWS HOW IMMUNE CELLS ORGANIZE THEMSELVES IN New research reveals how the skin’s immune cells organize themselves to ward off would-be intruders. Skin’s immune cells have a history of being misunderstood. SKINSAFE, CVS NAME TOP 25 2021 SUNSCREEN AWARD WINNERS FOR June 7, 2021 SkinSAFE, CVS Name Top 25 2021 Sunscreen Award Winners for Sensitive Skin Developed in collaboration with Mayo Clinic, SkinSAFE helps people with sensitive skin find products that meet their sensitive skin needs, and to avoid products that may contain potential irritants. EXPLORING THE CONNECTION BETWEEN GUT HEALTH AND HAIR The Gut/Hair Connection. Evolving indicators suggest a connection between gut health and hair growth that remains to be proven. For example, when two refractory alopecia universalis patients underwent fecal-matter transplant (FMT) for recurrent Clostridium difficile infection (CDI), they experienced subsequent hair regrowth.This suggests gut flora composition may be associated with immune FDA GRANTS BREAKTHROUGH DEVICE STATUS TO ALPHA DART FOR June 8, 2021 FDA Grants Breakthrough Device Status to Alpha DaRT for SCC The FDA granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma of the skin and oral cavity without curative standard ofcare.
CUTANEOUS SUPERFICIAL LEIOMYOSARCOMA: A TREATMENT Superficial leiomyosarcoma (SLMS) is a rare sarcoma, which is further classified as either cutaneous or subcutaneous based on dermal location and site of origin. Cutaneous SLMS have excellent outcome with rare recurrence, whereas subcutaneous SLMS have high recurrence and metastatic rates. Wide excision with 2-5cm margins hashistorically been
DERMAVANT SUBMITS NDA FOR TAPINAROF FOR PSO Dermavant Sciences has submitted a New Drug Application (NDA) to the FDA for tapinarof for the treatment of mild, moderate, and severeplaque psoriasi
dermwire-old Created with Sketch.AND
dermtube-old Created with Sketch. ARE NOW A PART OF THE NEW AND IMPROVED PD-Mobile-Logo Created with Sketch.* Current Issue
* Archive
* Dermtube Videos
* Dermwire News
*
More
downarrow Created with Sketch.* About
* Submissions
* Subscribe
* Events
* Podcasts
* Topics
search Created with Sketch. search Created with Sketch. search Created with Sketch.* Current Issue
* Archive
* Dermtube Videos
* Dermwire News
*
Topics
downarrow Created with Sketch.* Acne
* Cosmetic
* Eczema
* Infections
* Pediatric
* Practice Management* Psoriasis
* Residents
* Rosacea
* Skin Cancer
* Skin of Color
* About
* Submissions
* Subscribe
* Events
* Podcasts
TOPICS:
Acne
Cosmetic
Eczema
Infections
Pediatric
Practice Management
Psoriasis
Residents
Rosacea
Skin Cancer
Skin of Color
Advertisement
LEO PHARMA ENTERS LICENSE AGREEMENT WITH ONENESS BIOTECH, MICROBIO SHANGHAI FOR ATOPIC DERMATITIS AND ASTHMA DRUG CANDIDATE arrow-right Created with Sketch. arrow-right Created with Sketch. LEO PHARMA ENTERS LICENSE AGREEMENT WITH ONENESS BIOTECH, MICROBIO SHANGHAI FOR ATOPIC DERMATITIS AND ASTHMA DRUG CANDIDATE DERMWIRETV: COVID-19 LOANS, TALTZ FOR PEDS, FINACEA RETURNS arrow-right Created with Sketch. arrow-right Created with Sketch. DERMWIRETV: COVID-19 LOANS, TALTZ FOR PEDS, FINACEA RETURNS COVID-19 BY THE NUMBERS: APRIL 14 EDITION arrow-right Created with Sketch. arrow-right Created with Sketch. COVID-19 BY THE NUMBERS: APRIL 14 EDITION INDUSTRY RESPONDS TO COVID-19: HENRY SCHEIN MEDICAL, PCA SKIN arrow-right Created with Sketch. arrow-right Created with Sketch. INDUSTRY RESPONDS TO COVID-19: HENRY SCHEIN MEDICAL, PCA SKIN ROSACEA AWARENESS MONTH BRINGS FOCUS TO COMMON SKIN DISEASE arrow-right Created with Sketch. arrow-right Created with Sketch. ROSACEA AWARENESS MONTH BRINGS FOCUS TO COMMON SKIN DISEASE COVID-19 BY THE NUMBERS: APRIL 7 EDITION arrow-right Created with Sketch. arrow-right Created with Sketch. COVID-19 BY THE NUMBERS: APRIL 7 EDITION BREAKING A SWEAT: TREATING HYPERHIDROSIS IN THE COVID-19 ERA arrow-right Created with Sketch. arrow-right Created with Sketch. BREAKING A SWEAT: TREATING HYPERHIDROSIS IN THE COVID-19 ERA Neal Bhatia, MD, FAAD INJECTABLE BEAUTY: NEW USES FOR DERMAL FILLERS arrow-right Created with Sketch. arrow-right Created with Sketch. INJECTABLE BEAUTY: NEW USES FOR DERMAL FILLERSJeanette Black, MD
CSF LIVE VIRTUAL MEETING TO ASSESS SBA LOANS: TONIGHT arrow-right Created with Sketch. arrow-right Created with Sketch. CSF LIVE VIRTUAL MEETING TO ASSESS SBA LOANS: TONIGHT DIGITAL V. STANDARD PHOTOGRAPHY: WHEN AND WHY arrow-right Created with Sketch. arrow-right Created with Sketch. DIGITAL V. STANDARD PHOTOGRAPHY: WHEN AND WHY Todd E. Schlesinger, MD INDUSTRY RESPONDS TO COVID-19: ALLERGAN FOUNDATION; AG HAIR; REVANCE arrow-right Created with Sketch. arrow-right Created with Sketch. INDUSTRY RESPONDS TO COVID-19: ALLERGAN FOUNDATION; AG HAIR; REVANCE TELEHEALTH WEBINAR FROM COSMETIC SURGERY FORUM EXPLORES BEST PRACTICES arrow-right Created with Sketch. arrow-right Created with Sketch. TELEHEALTH WEBINAR FROM COSMETIC SURGERY FORUM EXPLORES BEST PRACTICES NEW AAAHC COVID-19 GUIDELINES CALL FOR POSTPONING ELECTIVE OR NON-ESSENTIAL VISITS AND SURGERIES arrow-right Created with Sketch. arrow-right Created with Sketch. NEW AAAHC COVID-19 GUIDELINES CALL FOR POSTPONING ELECTIVE OR NON-ESSENTIAL VISITS AND SURGERIES SPECIAL REPORT: COVID-19: SURGEONS SUPPORT FRONT LINES, HOW TO COPE arrow-right Created with Sketch. arrow-right Created with Sketch. SPECIAL REPORT: COVID-19: SURGEONS SUPPORT FRONT LINES, HOW TO COPE ADVANCES IN TATTOO REMOVAL AND MORE arrow-right Created with Sketch. arrow-right Created with Sketch. ADVANCES IN TATTOO REMOVAL AND MOREEric Bernstein, MD
SPECIAL REPORT: COVID-19 IMPACT AND RESPONSE arrow-right Created with Sketch. arrow-right Created with Sketch. SPECIAL REPORT: COVID-19 IMPACT AND RESPONSE ZYLÖ THERAPEUTICS A FINALIST IN THE BUZZ OF BIO CONTEST arrow-right Created with Sketch. arrow-right Created with Sketch. ZYLÖ THERAPEUTICS A FINALIST IN THE BUZZ OF BIO CONTEST HHS OCR: NEW HIPAA GUIDANCE TO SUPPORT E-CONSULTS arrow-right Created with Sketch. arrow-right Created with Sketch. HHS OCR: NEW HIPAA GUIDANCE TO SUPPORT E-CONSULTS AMA: NEW CPT CODE TO REPORT NOVEL CORONAVIRUS TEST arrow-right Created with Sketch. arrow-right Created with Sketch. AMA: NEW CPT CODE TO REPORT NOVEL CORONAVIRUS TEST SPECIAL REPORT: AN OVERVIEW OF CORONAVIRUS BY DR. JONATHAN KAPLAN arrow-right Created with Sketch. arrow-right Created with Sketch. SPECIAL REPORT: AN OVERVIEW OF CORONAVIRUS BY DR. JONATHAN KAPLAN NEAUVIA’S INTRODUCES ZAFFIRO, A TWO-PART SOLUTION TO SKINREJUVENATION
arrow-right Created with Sketch. arrow-right Created with Sketch. NEAUVIA’S INTRODUCES ZAFFIRO, A TWO-PART SOLUTION TO SKINREJUVENATION
DERMATOLOGIST URGES VIGILANCE FOR EXANTHEM AS CORONAVIRUS SPREADS arrow-right Created with Sketch. arrow-right Created with Sketch. DERMATOLOGIST URGES VIGILANCE FOR EXANTHEM AS CORONAVIRUS SPREADS INTERNATIONAL PSORIASIS COUNCIL OFFERS GUIDANCE ON MANAGING COVID-19 IN PEOPLE WITH PSORIASIS arrow-right Created with Sketch. arrow-right Created with Sketch. INTERNATIONAL PSORIASIS COUNCIL OFFERS GUIDANCE ON MANAGING COVID-19 IN PEOPLE WITH PSORIASIS FDA ACCEPTS NDA FOR ALMIRALL'S AK DRUG TIRBANIBULIN arrow-right Created with Sketch. arrow-right Created with Sketch. FDA ACCEPTS NDA FOR ALMIRALL'S AK DRUG TIRBANIBULIN GALDERMA ROLLS OUT NEW CONSUMER-FACING REWARDS APP, PLUS MORE arrow-right Created with Sketch. arrow-right Created with Sketch. GALDERMA ROLLS OUT NEW CONSUMER-FACING REWARDS APP, PLUS MOREGET THE GIST
arrow-right Created with Sketch. arrow-right Created with Sketch.GET THE GIST
Joel L. Cohen, MD; and Ava Shamban, MD, FAAD DERMATOLOGISTS REACT TO THREAT OF CORONAVIRUS PANDEMIC arrow-right Created with Sketch. arrow-right Created with Sketch. DERMATOLOGISTS REACT TO THREAT OF CORONAVIRUS PANDEMIC CYNOSURE'S FOUR-MODE RF MICRONEEDLING DEVICE CLEARED FOR MARKETING arrow-right Created with Sketch. arrow-right Created with Sketch. CYNOSURE'S FOUR-MODE RF MICRONEEDLING DEVICE CLEARED FOR MARKETING DERMWIRETV: SUN'S PSO IMPACT SURVEY, DERMATOLOGY.COM EXPANSION, MORE arrow-right Created with Sketch. arrow-right Created with Sketch. DERMWIRETV: SUN'S PSO IMPACT SURVEY, DERMATOLOGY.COM EXPANSION, MORE SUN PHARMA SURVEY: IMPACT OF PSORIASIS ON PATIENTS IS EXTENSIVE arrow-right Created with Sketch. arrow-right Created with Sketch. SUN PHARMA SURVEY: IMPACT OF PSORIASIS ON PATIENTS IS EXTENSIVE HALF OF LUPUS RASHES HARBOR HIGH LEVELS OF STAPH BACTERIA arrow-right Created with Sketch. arrow-right Created with Sketch. HALF OF LUPUS RASHES HARBOR HIGH LEVELS OF STAPH BACTERIA REVANCE: FDA ACCEPTS BLA FOR DAXIBOTULINUMTOXINA, SETS NOVEMBER PDUFADATE
arrow-right Created with Sketch. arrow-right Created with Sketch. REVANCE: FDA ACCEPTS BLA FOR DAXIBOTULINUMTOXINA, SETS NOVEMBER PDUFADATE
COLD PLASMA PATCH MAY MAKE IMMUNOTHERAPY MORE EFFECTIVE FOR TREATINGMELANOMA
arrow-right Created with Sketch. arrow-right Created with Sketch. COLD PLASMA PATCH MAY MAKE IMMUNOTHERAPY MORE EFFECTIVE FOR TREATINGMELANOMA
MATTEL RELEASES NEW BARBIE DOLLS WITH VITILIGO, ALOPECIA arrow-right Created with Sketch. arrow-right Created with Sketch. MATTEL RELEASES NEW BARBIE DOLLS WITH VITILIGO, ALOPECIA FDA FOLLOW-UP STUDY: SUNSCREEN ACTIVE INGREDIENTS ARE ABSORBED BYBLOODSTREAM
arrow-right Created with Sketch. arrow-right Created with Sketch. FDA FOLLOW-UP STUDY: SUNSCREEN ACTIVE INGREDIENTS ARE ABSORBED BYBLOODSTREAM
DERMWIRETV: MEET CROWN AESTHETICS, REVANCE TO MARKET TEOXANE FILLERS, ALMIRALL COLLABORATES arrow-right Created with Sketch. arrow-right Created with Sketch. DERMWIRETV: MEET CROWN AESTHETICS, REVANCE TO MARKET TEOXANE FILLERS, ALMIRALL COLLABORATES REVANCE ACQUIRES EXCLUSIVE US DISTRIBUTION RIGHTS TO TEOXANE SAFILLERS
arrow-right Created with Sketch. arrow-right Created with Sketch. REVANCE ACQUIRES EXCLUSIVE US DISTRIBUTION RIGHTS TO TEOXANE SAFILLERS
REVIAN AWARDED PATENT FOR BIOSTIMULATORY LIGHT COMBINATIONS arrow-right Created with Sketch. arrow-right Created with Sketch. REVIAN AWARDED PATENT FOR BIOSTIMULATORY LIGHT COMBINATIONS AMOREPACIFIC SHOWS OFF FACE MASK 3D PRINTING SYSTEM AND FLEXIBLE LED BEAUTY DEVICE AT CES 2020 arrow-right Created with Sketch. arrow-right Created with Sketch. AMOREPACIFIC SHOWS OFF FACE MASK 3D PRINTING SYSTEM AND FLEXIBLE LED BEAUTY DEVICE AT CES 2020 DERMWIRE EXCLUSIVE: MEET ALLĒ, ALLERGAN’S UPGRADED PATIENT LOYALTYPROGRAM
arrow-right Created with Sketch. arrow-right Created with Sketch. DERMWIRE EXCLUSIVE: MEET ALLĒ, ALLERGAN’S UPGRADED PATIENT LOYALTYPROGRAM
MARKETING TRENDS IN 2020 – DERMATOLOGY GETS MORE SOCIAL arrow-right Created with Sketch. arrow-right Created with Sketch. MARKETING TRENDS IN 2020 – DERMATOLOGY GETS MORE SOCIALEkwa Marketing
2019 IN REVIEW
arrow-right Created with Sketch. arrow-right Created with Sketch.2019 IN REVIEW
INDIAN INNOVATIONS
arrow-right Created with Sketch. arrow-right Created with Sketch.INDIAN INNOVATIONS
Chytra Anand, MD; and Joel L. Cohen, MD, FAAD 2019 MEDICAL AESTHETIC TRENDS arrow-right Created with Sketch. arrow-right Created with Sketch. 2019 MEDICAL AESTHETIC TRENDS Joel L. Cohen, MD, FAAD*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Advertisement
THE LATEST
Acne
Cosmetic
Eczema
Infections
Pediatric
Practice Management
Psoriasis
Residents
Rosacea
Skin Cancer
Skin of Color
VIEW MORE +
NEWS | APRIL 18, 2020 Can JAK Inhibition Put the Brakes on COVID-19-Associated Cytokine Storm? Incyte Hopes So NEWS | APRIL 17, 2020 Industry Responds to COVID-19: UCB, Galderma, Timeless Skin Care NEWS | APRIL 17, 2020 LEO Pharma Enters License Agreement with Oneness Biotech, Microbio Shanghai for Atopic Dermatitis and Asthma Drug Candidate VIDEO | APRIL 16, 2020 DermWireTV: COVID-19 Loans, Taltz for Peds, Finacea ReturnsDermWire TV
subscribe Created with Sketch.Subscribe
calendar Created with Sketch.Events
CME Created with Sketch.CME
Advertisement
NEWS | APRIL 16, 2020 DermWire Exclusive: Inside the COVID-19 Outbreak in Italy with Dr. Sebastiano Recalcati NEWS | APRIL 16, 2020 Kubota Vision, LEO Pharma A/S to Screen Novel VAP-1 Inhibitors for Inflammatory Skin DiseasesARTICLE | MAY 2020
SURVIVAL OF THE FITTEST Neal Bhatia, MD, FAAD VIDEO | APRIL 16, 2020 QUARANTINE QUORUM: CIRCLING THE WAGONSDerm Insider
With Quarantine Quorum, host Neal Bhatia, MD provides a diary of life during the COVID-19 pandemic, talking to members of the dermatologycommunity as...
Neal Bhatia, MD, FAAD; Hilary Baldwin, MD; Adam Friedman, MD, FAAD; Mark D. Kaufmann, MD, FAAD; and James Q. Del Rosso, DO NEWS | APRIL 16, 2020 San Diego Dermatology Symposium Reschedules to September NEWS | APRIL 15, 2020 Navigating the Ins and Outs of Your Insurance Coverage During COVID-19 NEWS | APRIL 15, 2020 New Melanoma Test May Reduce Unnecessary Lymph Node Biopsies VIDEO | APRIL 15, 2020 IS IT TIME TO CONSIDER TELEMEDICINE AT YOUR DERMATOLOGY PRACTICE? Telemedicine is in high demand, now more than ever. This Ekwa Marketing video explores how well it fits with dermatology...Ekwa Marketing
NEWS | APRIL 15, 2020 Finacea Foam Back in Pharmacies: LEO Pharma NEWS | APRIL 14, 2020 COVID-19 By the Numbers: April 14 Edition RESIDENT RESOURCE CENTER|
APRIL 2020
THE EFFECT OF CLEANSERS ON THE SKIN MICROBIOME DeAnna Diaz, MS, MBS, OMS-III, and Chérie M. Ditre, MDTHERAPEUTICS UPDATE
|
APRIL 2020
NEW IN MY PRACTICE: OTCCLINICAL FOCUS
| APRIL
2020
AN UPDATE ON THE USE OF TRIFAROTENE FOR THE TREATMENT OF ACNE Trifarotene is the first novel topical retinoid approved for the treatment of facial and truncal acne in 20 years.Joshua Zeichner, MD
AESTHETICS MANAGEMENT|
APRIL 2020
FACING CHALLENGES: ADAPTING PRACTICE IN THE FACE OF COVID-19 CSF Faculty share experiences and tips for practicing in the “newnormal.”
Joel Schlessinger, MD, FAADFEATURES |
APRIL 2020
PHASE 2 AND 3 TRIALS OF JAK INHIBITORS FOR ATOPIC DERMATITIS: A REVIEW A number of drugs in development show promise for one of the most challening skin diseases. Donovan G. Kearns, BS; Shelley K. Uppal, BS; Vipawee S. Chat, BS; and Jashin J. Wu, MD, FAADFEATURES |
APRIL 2020
10 WAYS TO MAINTAIN STAFF MORALE DURING THE COVID-19 CRISIS AND POSITION YOUR PRACTICE TO BOUNCE BACK Ten strategies to consider, even if your office is closed or your staff are furloughed. Kasey D’Amato, PA-CView more
MODERN AESTHETIC SERIES Experts tackle issues that matter to dermatologists, plastic surgeons, and other aesthetic specialists during the COVID-19 crisis.View Series
BREAKING NEWS
Get updates on the impact of COVID-19 from _Practical Dermatology_®View News
STAY UP TO DATE
Stay up to date on all things Dermatology by signing up to recieve our print publication or subscribe to our email alerts. email-new Created with Sketch. Sign Up INTERESTED IN AESTHETICS? Check out Modern Aesthetics®, our sister publication to see the latest expert advice and innovations in aesthetics. Visit Modern AestheticsAdvertisement
EVENTS
CANCELLED - ASLMS
April 29 - May 3, 2020 Phoenix Convention Center and Hyatt Regency Phoenix/Sheraton GrandPhoenix
DERM2020
August 6 - 9, 2020
Encore
View More Events
FEATURED VIDEO SERIESSponsored
dermwire-tv-logo Created with Sketch.Sponsored
ask-an-expert Created with Sketch. dt-jc Created with Sketch.Sponsored
View More +
MEETING COVERAGE
IMCASWorldCongress2019 Created with Sketch. AADAnnualMeeting2019 Created with Sketch. aad2019-summer-logo Created with Sketch.View More +
TOPICS:
Acne
Cosmetic
Eczema
Infections
Pediatric
Practice Management
Psoriasis
Residents
Rosacea
Skin Cancer
Skin of Color
* Current Issue
* Archive
* Dermtube Videos
* Dermwire News
* Topics
* About
* Submissions
* Subscribe
* Events
* Contact
Practical Dermatology® is a publication dedicated to providing the latest developments in medical and cosmetic dermatology. twitter Created with Sketch. facebook Created with Sketch. twitter Created with Sketch. linkedin Created withSketch.
book Created with Sketch. Start Your Free Print Subscription Today email-new Created with Sketch. Stay Updated:Subscribe to our E-blasts PD-BMC-Group Created with Sketch. 2020 Bryn Mawr Communications III, LLC. All RIghts Reserved •Privacy Policy
onetrust-logo Created with Sketch.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0